Drug intelligence / Profile preview

RKD004

Development stage: Preclinical
Lead developer: RevolKa
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Parenteral

Overview

RKD004 is a preclinical-stage mRNA-based therapeutic candidate being developed by RevolKa for the treatment of an undisclosed rare disease. The program utilizes RevolKa's proprietary protein engineering platform, which combines directed evolution with artificial intelligence to design novel, optimized proteins. RKD004 specifically employs a gain-of-function (GOF)-enhanced mRNA designed to express an AI-engineered enzyme within the patient's cells. This approach is intended to restore or enhance enzymatic activity to treat genetic or metabolic disorders. The development of RKD004 is being conducted in collaboration with an undisclosed partner, and the specific molecular target of the enzyme has not been publicly revealed.

Beyond the preview

Go deeper on RKD004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RKD004.

Explore the full profile